JP6951826B2 - ヒト化抗ｃｄ３抗体、その複合体、およびその使用 - Google Patents

ヒト化抗ｃｄ３抗体、その複合体、およびその使用 Download PDF

Info

Publication number
JP6951826B2
JP6951826B2 JP2018539317A JP2018539317A JP6951826B2 JP 6951826 B2 JP6951826 B2 JP 6951826B2 JP 2018539317 A JP2018539317 A JP 2018539317A JP 2018539317 A JP2018539317 A JP 2018539317A JP 6951826 B2 JP6951826 B2 JP 6951826B2
Authority
JP
Japan
Prior art keywords
amino acid
antibody
acid sequence
seq
sequence comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018539317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512002A5 (https=
JP2019512002A (ja
Inventor
キム，チャンヒョク
ヤング，トラヴィス
キム，ミンスー
マ，ジェニファー
プレスタ，レオナルド
ジー． シュルツ，ピーター
ジー． シュルツ，ピーター
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2019512002A publication Critical patent/JP2019512002A/ja
Publication of JP2019512002A5 publication Critical patent/JP2019512002A5/ja
Priority to JP2021153453A priority Critical patent/JP2022023052A/ja
Application granted granted Critical
Publication of JP6951826B2 publication Critical patent/JP6951826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018539317A 2016-02-04 2017-02-03 ヒト化抗ｃｄ３抗体、その複合体、およびその使用 Active JP6951826B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021153453A JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291143P 2016-02-04 2016-02-04
US62/291,143 2016-02-04
PCT/US2017/016407 WO2017136659A2 (en) 2016-02-04 2017-02-03 Humanized anti-cd3 antibodies, conjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021153453A Division JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Publications (3)

Publication Number Publication Date
JP2019512002A JP2019512002A (ja) 2019-05-09
JP2019512002A5 JP2019512002A5 (https=) 2020-03-26
JP6951826B2 true JP6951826B2 (ja) 2021-10-20

Family

ID=59501004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018539317A Active JP6951826B2 (ja) 2016-02-04 2017-02-03 ヒト化抗ｃｄ３抗体、その複合体、およびその使用
JP2021153453A Pending JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021153453A Pending JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Country Status (9)

Country Link
US (1) US12252534B2 (https=)
EP (1) EP3411069B1 (https=)
JP (2) JP6951826B2 (https=)
KR (1) KR102891788B1 (https=)
CN (1) CN109069635B (https=)
AU (1) AU2017213886B2 (https=)
CA (1) CA3013463C (https=)
ES (1) ES2992761T3 (https=)
WO (1) WO2017136659A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
KR102891788B1 (ko) 2016-02-04 2025-11-26 더 스크립스 리서치 인스티튜트 인간화 항-cd3 항체, 접합체 및 이의 용도
WO2019034580A1 (en) 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
MX2021002301A (es) * 2018-08-28 2021-04-28 Ambrx Inc Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
US20220089722A1 (en) * 2018-12-29 2022-03-24 Nantong Yichen Biopharma. Co. Ltd. Heterodimeric fusion protein
CN112703013B (zh) * 2019-02-22 2022-09-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用
WO2020232165A1 (en) * 2019-05-14 2020-11-19 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
TWI841790B (zh) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 靶向cd3的抗體、雙特異性抗體及其用途
EP4063387A4 (en) * 2019-11-22 2023-08-02 Nantong Yichen Biopharma. Co. Ltd. PSMA ANTIBODIES AND ITS USE
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
TWI827807B (zh) * 2020-02-26 2024-01-01 香港商潤俊（中國）有限公司 抗cd3抗體葉酸生物共軛物及其用途
JP7518286B2 (ja) 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
JP2025540657A (ja) * 2022-11-18 2025-12-16 ジェイエヌ バイオサイエンシーズ エルエルシー 抗ｃｄ３抗体
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法
WO2024191168A1 (ko) * 2023-03-13 2024-09-19 머스트바이오 주식회사 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체
CN121135889A (zh) * 2024-06-13 2025-12-16 合肥天港免疫药物有限公司 靶向b7h7和cd3的双特异性抗体及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
CN1589151A (zh) 2001-09-21 2005-03-02 图兰恩教育基金管理人 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
EP1732153A4 (en) 2004-03-30 2012-05-16 Kureha Corp MATERIAL FOR NEGATIVE ELECTRODE OF NONAQUEOUS ELECTROLYTIC SECONDARY CELL; PROCESS FOR PRODUCING THE SAME; NEGATIVE ELECTRODE AND BATTERY
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2007058725A2 (en) * 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
DK2339014T3 (en) 2005-11-16 2015-07-20 Ambrx Inc Methods and compositions comprising non-natural amino acids
WO2007070659A2 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN105085313A (zh) 2005-12-30 2015-11-25 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
AU2007215566A1 (en) 2006-01-19 2007-08-23 Ambrx, Inc. Non-natural amino acid polypeptides having modulated immunogenicity
CN101578264A (zh) 2006-12-18 2009-11-11 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
US20100098630A1 (en) 2006-12-28 2010-04-22 Ambrx, Inc. Phenazine and Quinoxaline Substituted Amino Acids and Polypeptides
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
HRP20151367T1 (hr) 2008-05-13 2016-01-29 Yale University Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
WO2012098238A1 (en) * 2011-01-21 2012-07-26 Novimmune S.A. Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
KR102060389B1 (ko) 2011-05-21 2019-12-31 마크로제닉스, 인크. 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
KR102356286B1 (ko) 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
RU2015117393A (ru) * 2012-10-08 2016-12-10 Роше Гликарт Аг Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
TW201446804A (zh) 2013-05-14 2014-12-16 Ambrx公司 新穎多肽小分子結合物及其用途
SI3004106T1 (en) 2013-06-07 2018-03-30 Rhizen Pharmaceuticals S.A. Dual selective PI3 delta and gamma inhibitors
CN105814083A (zh) * 2013-10-15 2016-07-27 加州生物医学研究所 嵌合抗原受体t细胞开关和其用途
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
KR102891788B1 (ko) 2016-02-04 2025-11-26 더 스크립스 리서치 인스티튜트 인간화 항-cd3 항체, 접합체 및 이의 용도

Also Published As

Publication number Publication date
CA3013463A1 (en) 2017-08-10
WO2017136659A3 (en) 2017-09-08
CN109069635B (zh) 2023-09-26
EP3411069A4 (en) 2020-02-19
EP3411069B1 (en) 2024-07-10
JP2022023052A (ja) 2022-02-07
KR102891788B1 (ko) 2025-11-26
KR20180104157A (ko) 2018-09-19
US20230192844A1 (en) 2023-06-22
AU2017213886A1 (en) 2018-08-16
ES2992761T3 (en) 2024-12-17
AU2017213886B2 (en) 2024-03-07
CA3013463C (en) 2024-05-21
WO2017136659A2 (en) 2017-08-10
JP2019512002A (ja) 2019-05-09
CN109069635A (zh) 2018-12-21
EP3411069A2 (en) 2018-12-12
US12252534B2 (en) 2025-03-18

Similar Documents

Publication Publication Date Title
JP6951826B2 (ja) ヒト化抗ｃｄ３抗体、その複合体、およびその使用
TWI815815B (zh) Bcma單株抗體-藥物結合物
US12377163B2 (en) Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
JP2025060760A (ja) アマトキシン抗体薬物複合体及びその使用
JP7042876B2 (ja) Ｃｙｓ８０抱合型免疫グロブリン
TWI904109B (zh) 抗ｃｄ４５抗體及其結合物
CA3166139C (en) Engineered anti-il-2 antibodies
TW201832778A (zh) 對ａｓｃｔ２具有特異性的結合分子及其用途
JP2025508009A (ja) ＦＲαに対する結合分子
BR112021003843A2 (pt) biconjugados de folato de anticorpo anti-cd3 e seus usos
WO2021173889A1 (en) Uses of anti-cd3 antibody folate bioconjugates
JP7762294B2 (ja) 抗ｃｄ３９抗体ー薬物複合体及びその使用
JP2024544757A (ja) タンパク質複合体の組成物およびその使用方法
HK40000405B (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
HK40000405A (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
JP2025088767A (ja) ＰＳＭＡ－ＳＴＥＡＰ１二重可変ドメイン免疫グロブリン（ＤＶＤ－Ｉｇ）分子及び薬物コンジュゲート
WO2026015981A1 (en) Degrader drug conjugates and methods of use thereof
AU2024389066A1 (en) Psma-steap1 dual variable domain immunoglobulin (dvd-ig) molecules and drug conjugates
TW202604959A (zh) 抗EGFR×cMet雙特異性抗體的藥物偶聯物及其用途
JP2026506049A (ja) 治療用結合分子を用いた癌の治療のための併用療法
HK40094038A (zh) 抗体药物缀合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210924

R150 Certificate of patent or registration of utility model

Ref document number: 6951826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250